--- title: "Abeona Therapeutics (ABEO) news: offering" url: "https://aibio.space/companies/abeona-therapeutics/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "ABEO offering news: Abeona Therapeutics cuts term loan rate to 11.75% and issues Avenue warrants. Abeona Therapeutics Inc. (NASDAQ: ABEO), United States." --- ABEO Abeona Therapeutics Inc. NASDAQ · United States # Abeona Therapeutics (ABEO) news ABEO offering news Debt Financing · 2025-07-18 ## [Abeona Therapeutics cuts term loan rate to 11.75% and issues Avenue warrants](https://aibio.space/news/abeona-therapeutics-cuts-term-loan-rate-11-75-percent-issues-avenue/) Abeona Therapeutics lowered the rate on its senior secured term loan from 13.5% to a fixed 11.75% and gave the Avenue lenders warrants for up to 16,474 shares at $6.07. Its 2024 net loss was $63.7 million, and its 10-K says $98.1 million in year-end cash and investments, plus later at-the-market proceeds, covers at least 12 months from issuance. ## Latest Abeona Therapeutics news 1. 2025-07-02 Financings [Abeona closes $155 million sale of rare pediatric disease priority review voucher](https://aibio.space/news/abeona-closes-155-million-sale-rare-pediatric-disease-priority-review/) Abeona received gross proceeds of $155 million on June 27, 2025. The company says unaudited cash, cash equivalents, restricted cash and short-term investments were approximately $225 million as of June 30, 2025. 2. 2025-07-02 Mergers [Abeona Therapeutics closes $155 million sale of priority review voucher](https://aibio.space/news/abeona-therapeutics-closes-155-million-sale-priority-review-voucher/) The sale closed on June 27, 2025. Abeona says cash and investments were about $225 million as of June 30, 2025, a figure it labels unaudited, and the release again does not name the buyer. 3. 2025-05-12 Financings [Abeona Therapeutics agrees to sell priority review voucher for $155 million](https://aibio.space/news/abeona-therapeutics-agrees-sell-priority-review-voucher-155-million/) Abeona received the voucher when the FDA approved ZEVASKYN on April 28, 2025. The company says the proceeds give it cash for more than two years of operating expenses, but the release does not name the buyer. ## Abeona Therapeutics at a glance - **Ticker**: ABEO - **Listing**: NASDAQ - **Country**: United States - **Cash, Jun 30, 2026**: $146.8 million ### Related companies - [Tonix Pharmaceuticals Holding](https://aibio.space/companies/tonix-pharmaceuticals/) NASDAQ: TNXP - [Rigel Pharmaceuticals](https://aibio.space/companies/rigel-pharmaceuticals/) NASDAQ: RIGL - [Sutro Biopharma](https://aibio.space/companies/sutro-biopharma/) NASDAQ: STRO - [Corvus Pharmaceuticals](https://aibio.space/companies/corvus-pharmaceuticals/) NASDAQ: CRVS - [Emmaus Life Sciences](https://aibio.space/companies/emmaus-life-sciences/) OTC: EMMA - [Quoin Pharmaceuticals](https://aibio.space/companies/quoin-pharmaceuticals/) NASDAQ: QNRX - [Aprea Therapeutics](https://aibio.space/companies/aprea-therapeutics/) NASDAQ: APRE - [Kairos Pharma](https://aibio.space/companies/kairos-pharma/) AMEX: KAPA ### Also on NASDAQ - [PULSE BIOSCIENCES, INC.](https://aibio.space/companies/pulse-biosciences/) PLSE - [ICU MEDICAL INC/DE](https://aibio.space/companies/icu-medical-de/) ICUI - [Monopar Therapeutics](https://aibio.space/companies/monopar-therapeutics/) MNPR - [Stoke Therapeutics](https://aibio.space/companies/stoke-therapeutics/) STOK - [Akari Therapeutics Plc](https://aibio.space/companies/akari-therapeutics/) AKTX - [NATURES SUNSHINE PRODUCTS INC](https://aibio.space/companies/natures-sunshine-products/) NATR ## What Abeona Therapeutics does Abeona Therapeutics is a commercial-stage biopharmaceutical company developing cell and gene therapies for life-threatening diseases. Its lead product, ZEVASKYN (prademagene zamikeracel), received FDA approval on April 28, 2025 as the first and only autologous cell-based gene therapy for the treatment of wounds in adult and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB), a serious genetic skin disease. ZEVASKYN is manufactured at Abeona's cGMP facility in Cleveland, Ohio, and is delivered through qualified treatment centers; as of March 2026 the company had activated 4 such centers and was in discussions with additional ones. Abeona also develops adeno-associated virus (AAV) gene therapies for ophthalmic diseases using its novel AIM capsids, and it licenses and invents capsid technology for a range of rare genetic diseases. The company partners with academic researchers, patient advocacy organizations, caregivers and other biotechnology companies, and it intends to commercialize its other assets either alone or through strategic partnerships. | Product or program | What it is | Stage | |---|---|---| | ZEVASKYN (prademagene zamikeracel) | Autologous cell-based gene therapy for wounds in recessive dystrophic epidermolysis bullosa | approved in the US | | AIM capsid AAV gene therapies | AAV-based gene therapies for ophthalmic diseases | | Summarised from the company's [10-K filed Mar 17, 2026](https://www.sec.gov/Archives/edgar/data/318306/000149315226010413/form10-k.htm). ## Abeona Therapeutics annual financials | Line | FY2025 | FY2024 | |---|---|---| | Research and development | [$26.8 million](https://www.sec.gov/Archives/edgar/data/318306/000149315226010413/) | [$34.4 million](https://www.sec.gov/Archives/edgar/data/318306/000149315226010413/) | | Net income (loss) | [$71.2 million](https://www.sec.gov/Archives/edgar/data/318306/000149315226010413/) | [-$63.7 million](https://www.sec.gov/Archives/edgar/data/318306/000149315226010413/) | | Cash from operations | [-$76.3 million](https://www.sec.gov/Archives/edgar/data/318306/000149315226010413/) | [-$56.0 million](https://www.sec.gov/Archives/edgar/data/318306/000149315226010413/) | | Cash and equivalents | [$78.4 million](https://www.sec.gov/Archives/edgar/data/318306/000149315226037576/) | [$23.4 million](https://www.sec.gov/Archives/edgar/data/318306/000149315226010413/) | | Short-term investments | [$113.0 million](https://www.sec.gov/Archives/edgar/data/318306/000149315226037576/) | [$74.4 million](https://www.sec.gov/Archives/edgar/data/318306/000149315226010413/) | Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $56.2 million, plus short-term investments of $90.6 million, $146.8 million in all. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about Abeona Therapeutics Has Abeona Therapeutics raised money recently? Our latest story on this, dated Jul 18, 2025: "Abeona Therapeutics cuts term loan rate to 11.75% and issues Avenue warrants". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/abeona-therapeutics-cuts-term-loan-rate-11-75-percent-issues-avenue/). What is the ticker symbol of Abeona Therapeutics? Abeona Therapeutics Inc. trades under the ticker ABEO on NASDAQ. Where is Abeona Therapeutics listed? Abeona Therapeutics Inc. is listed on NASDAQ. Our directory also records these other listings: GETTEX:PCJ; LS:A3DMHM; LSE:0H7R; LSX:A3DMHM. What is the SEC CIK of Abeona Therapeutics? The SEC Central Index Key (CIK) for Abeona Therapeutics Inc. is 318306. Its filings are on SEC EDGAR. How many shares does Abeona Therapeutics have outstanding? 57,184,017 shares as of 2026-08-10, per the cover page of its 10-Q filed 2026-08-13. Which country or territory is Abeona Therapeutics listed under? Our directory records Abeona Therapeutics Inc. under United States. What does Abeona Therapeutics do? Our directory classifies Abeona Therapeutics Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline. What is the ISIN of Abeona Therapeutics? The ISIN recorded for Abeona Therapeutics Inc. is US00289Y2063. Does aibio.space cover Abeona Therapeutics? aibio.space lists Abeona Therapeutics Inc. among 2,820 public biotech companies and publishes its news here as stories appear. Where is Abeona Therapeutics incorporated? SEC records list its state or country of incorporation as DE. What does Abeona Therapeutics develop? Abeona Therapeutics is a commercial-stage biopharmaceutical company developing cell and gene therapies for life-threatening diseases. Its lead product, ZEVASKYN (prademagene zamikeracel), received FDA approval on April 28, 2025 as the first and only autologous cell-based gene therapy for the treatment of wounds in adult and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB), a serious genetic skin disease. What is ZEVASKYN (prademagene zamikeracel) from Abeona Therapeutics? ZEVASKYN (prademagene zamikeracel): Autologous cell-based gene therapy for wounds in recessive dystrophic epidermolysis bullosa Stage: approved in the US. What is AIM capsid AAV gene therapies from Abeona Therapeutics? AIM capsid AAV gene therapies: AAV-based gene therapies for ophthalmic diseases Is Abeona Therapeutics profitable? Abeona Therapeutics Inc. reported net income of $71.2 million for the fiscal year ended Dec 31, 2025, and used $76.3 million of cash in operations, per its annual report to the SEC. How much does Abeona Therapeutics spend on research and development? $26.8 million in the fiscal year ended Dec 31, 2025, per its annual report. ## Investor discussion: Abeona Therapeutics Members talk about Abeona Therapeutics (ABEO). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at Abeona Therapeutics, newest first. Each line links the filing it comes from. 1. 2025-07-02 Mergers Reported completing an acquisition or a sale of assets. SEC Form 8-K (Items 2.01,2.02,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/318306/000164117225017460/ex99-1.htm) 2. 2025-05-12 Financings Reported a financing. SEC Form 8-K (Items 1.01,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/318306/000164117225009564/ex99-1.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:ABEO on TradingView](https://www.tradingview.com/symbols/NASDAQ-ABEO/). ## SEC filings and registration - **SEC name**: Abeona Therapeutics Inc. - **CIK**: 318306 - **Industry (SIC)**: Pharmaceutical Preparations (2834) - **US tickers**: ABEO (Nasdaq) - **State or country of incorporation**: DE - **Fiscal year ends**: December 31 - **Filer category**: Non-accelerated filer
Smaller reporting company - **Business address**: 6555 CARNEGIE AVE, 4TH FLOOR, CLEVELAND, OH, 44103 - **Phone**: 646-813-4701 - **Shares outstanding**: 57,184,017 as of 2026-08-10 (10-Q filed 2026-08-13) - **Former names**: PLASMATECH BIOPHARMACEUTICALS INC; ACCESS PHARMACEUTICALS INC; CHEMEX PHARMACEUTICALS INC ### Recent filings (8-K and 6-K are the company's own announcements) - [8-K](https://www.sec.gov/Archives/edgar/data/318306/000149315226042702/form8-k.htm) filed 2026-09-15 - [10-Q](https://www.sec.gov/Archives/edgar/data/318306/000149315226037576/form10-q.htm) filed 2026-08-13 - [8-K](https://www.sec.gov/Archives/edgar/data/318306/000149315226037575/form8-k.htm) filed 2026-08-13 - [8-K](https://www.sec.gov/Archives/edgar/data/318306/000149315226028458/form8-k.htm) filed 2026-06-12 - [8-K](https://www.sec.gov/Archives/edgar/data/318306/000149315226028369/form8-k.htm) filed 2026-06-12 - [8-K](https://www.sec.gov/Archives/edgar/data/318306/000149315226028106/form8-k.htm) filed 2026-06-10 - [8-K](https://www.sec.gov/Archives/edgar/data/318306/000149315226027197/form8-k.htm) filed 2026-06-04 - [10-Q](https://www.sec.gov/Archives/edgar/data/318306/000149315226022614/form10-q.htm) filed 2026-05-13 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000318306), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details Abeona Therapeutics Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker ABEO, recorded under United States. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Abeona Therapeutics Inc. - **Ticker**: ABEO - **Listing**: NASDAQ - **Country or territory**: United States - **Business scope**: Pharmaceuticals: Major - **ISIN**: US00289Y2063 - **Other listed symbols**: GETTEX:PCJ; LS:A3DMHM; LSE:0H7R; LSX:A3DMHM - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-ABEO/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/abeona-therapeutics/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Abeona Therapeutics (ABEO) news: offering", 2026-10-31, https://aibio.space/companies/abeona-therapeutics/